 |
0 Diseases |  |
0 Trials |
|
0 Trials |  |
14 News |  |
- Memogain (galantamine prodrug) / Alpha Cognition
A Quantitative-EEG Assessment of Alpha-1062, a Novel Pro-Drug of Galantamine for the Treatment of Mild to Moderate Dementia Associated with Alzheimer’s Disease. () - Jun 24, 2022 - Abstract #AAIC2022AAIC_361;
- Memogain (galantamine prodrug) / Alpha Cognition
Evaluation of Pharmaco EEG Outcomes in Subjects Administered Alpha-1062 a Galantamine Prodrug in a Multiple Ascending Dose Study (Poster hall) - Aug 7, 2021 - Abstract #CTAD2021CTAD_160;
- Memogain (galantamine prodrug) / Alpha Cognition
[VIRTUAL] MUTATION SPECTRUM OF F11 GENE IN HEMOPHILIA C PATIENTS FROM RUSSIA () - Jan 8, 2021 - Abstract #EAHAD2021EAHAD_245;
In four cases homozygous mutations or a compound of two missense mutations resulted in a considerable reduction of FXI (0.1‐2%). In other patients with heterozygous mutations the factor level varied from 32.4 to 58.6%.
- | TY101 / Tayu Huaxia Biotech, Memogain (galantamine prodrug) / Alpha Cognition
Journal: The Dual-Targeting Activity of the Metabolite Substrate of Para-amino Salicyclic Acid in the Mycobacterial Folate Pathway: Atomistic and Structural Perspectives. (Pubmed Central) - Nov 21, 2020
These conformational changes possibly interfered with the biological functions of the enzymes and hence their inhibition as experimentally reported. Structural Insights provided could open up a novel paradigm of structure-based design of multi-targeting inhibitors of biological targets in the folate biosynthetic pathway toward tuberculosis therapy.
- || galantamine hydrobromide / Generic mfg.
Clinical, PK/PD data, Journal: Safety, pharmacokinetics, and pharmacodynamics of Gln-1062, a prodrug of galantamine. (Pubmed Central) - Oct 23, 2020
Gln-1062 was considered to be safe and caused fewer gastrointestinal side effects than oral galantamine. Gln-1062 behaved pharmacokinetically as expected and improved performance on cognitive tests.